BNTX ▲ +0.4% - BioNTech SE
$BNTX - BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26-OCT-2026 05:00 AM ET
Share this post
More filings for $BNTX
BNTX ▼ -1.4% - BioNTech SEOct 25, 2026BNTX ▼ -0.7% - BioNTech SEOct 22, 2026BNTX ▲ +0.2% - BioNTech SEOct 19, 2026BNTX ▼ -1.2% - BioNTech SEOct 13, 2026BNTX ▲ +3.4% - BioNTech SESep 14, 2026BNTX ▼ -7.2% - BioNTech SEAug 28, 2026
View full $BNTX filing history →💬 Comments
Loading comments…
Leave a comment